心血管磁共振在肿瘤心脏病学中的应用:SCMR专家共识
本共识由心血管磁共振学会(SCMR)制定,旨在指导肿瘤患者中CMR的临床选择、时机、决策及方案设计。内容涵盖左心室功能、心肌应变、心肌损伤与水肿、心肌炎、血管毒性、铁过载、心脏淀粉样变、心包疾病、瓣膜病、肺动脉高压及心脏肿块等场景。部分推荐基于专家意见和公认最佳实践。
要点
- CMR可评估肿瘤患者LVEF与容积,用于已知或疑似心功能不全的决策
- 心肌应变与参数定量及LGE可识别临床前左心室功能障碍和心肌损伤
- CMR方案应针对具体临床问题定制,覆盖心肌炎、铁过载、淀粉样变等场景
核心结论
- CMR是肿瘤患者心血管疾病评估的重要工具,可用于左心室功能、心肌损伤、心肌炎、血管毒性、铁过载、心脏淀粉样变、心包疾病、瓣膜病、肺动脉高压及心脏肿块的检查。
研究设计与样本
- 本文为SCMR专家共识声明,由SCMR Cardio-Oncology共识组制定,经SCMR出版委员会和执行委员会背书。
- 共识覆盖放疗、造血干细胞移植、生存期及儿科等特殊情境,推荐部分基于专家意见和公认最佳实践。
诊断标准与关键数值
- 左心室功能障碍评估采用射血分数和容积;临床前左心室功能障碍采用心肌应变识别。
- 心肌损伤或水肿采用参数定量和晚期钆增强(LGE)评估;血管毒性重点关注冠状动脉疾病。
临床应用与阅片要点
- 根据具体临床问题定制CMR检查方案,而不采用统一固定序列。
- 在肿瘤患者中合理选择CMR时机,以支持临床决策。
- 需注意CMR并非在所有地区均可及,应结合可获得的影像资源综合判断。
局限性
- 作为专家共识,部分推荐基于专家意见而非高级别证据。
- 作者承认CMR并非始终可在本地获得或充分可及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This document represents a position statement from the Society for Cardiovascular Magnetic Resonance (SCMR) on recommendations for clinical utilization of cardiovascular magnetic resonance (CMR) in patients with cancer. The document was prepared by the SCMR Consensus Group on CMR Imaging for Cardio-Oncology and endorsed by the SCMR Publications Committee and SCMR Executive Committee. This document aims to: (1) guide the informed selection and timing of CMR; (2) inform clinical decision-making based on CMR findings; (3) educate stakeholders on the advantages and limitations of CMR in specific clinical scenarios; and (4) provide suggested protocols to tailor the CMR exam to the particular clinical question. The statements of clinical utility presented in the current document focus on the following clinical scenarios: evaluating left ventricular dysfunction with ejection fraction and volumes; identifying pre-clinical left ventricular (LV) dysfunction with myocardial strain; and myocardial injury or edema with parametric mapping and late gadolinium enhancement (LGE); myocarditis; vascular toxicity, with a focus on coronary artery disease (CAD); iron overload; cardiac amyloidosis; pericardial disease; valvular disease; pulmonary hypertension; and cardiac masses. Sections devoted to the special situations of radiation therapy (RT), hematopoietic stem cell transplantation (HSCT), and survivorship and pediatrics are also included. As an expert consensus statement, some recommendations are based on expert opinion and accepted best practices. This position statement emphasizes the optimal utilization of CMR in oncology patients with known or suspected cardiovascular disease; however, the authors acknowledge that CMR is not always locally available or accessible. Finally, the principal aim of this position statement is to provide specific recommendations on the use of CMR to help improve the health of cancer patients with cardiovascular disease.
引用
- Baldassarre, Reinhardt, Jordan, et al. Cardiovascular Magnetic Resonance Imaging in Cardio-Oncology: An Expert Consensus Statement from the Society for Cardiovascular Magnetic Resonance. Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Magn Reson. 2026. PMID: 42906855. doi:10.1016/j.jocmr.2026.102818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。